Phibro Animal Health Corporation (PAHC)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.42B
Last updated: Nov 17, 2026 at 4:15 PM ET
Phibro Animal Health Corporation (PAHC) Statistics
Phibro Animal Health (PAHC) has a market cap of $1.42B and an enterprise value of $2.08B. Its trailing P/E of 10.7x is below its 10-year median of 16.9x. Its return on invested capital of 11.69% compares with a 7.08% median across 10 similar companies.
Total Valuation
Enterprise value is 46.37% above the market cap, as debt exceeds cash.
| Market Cap | $1.42B |
|---|---|
| Enterprise Value | $2.08B |
| Latest price (Nov 17, 2026) | $34.92 |
Key Dates
The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Nov 25, 2026.
| Next Earnings Date | Feb 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Next Ex-Dividend Date | Nov 25, 2026 |
| Next Payment Date | Dec 16, 2026 |
| Fiscal Year End | June |
Valuation Ratios
Sales and book value multiples are 0.9x and 3.4x. Its year-end P/E ranged from 10.2x to 21.8x from 2016 to 2025.
| P/E Ratio | 10.7x |
|---|---|
| Forward P/E | 9.8x |
| P/S Ratio | 0.9x |
| Forward P/S | 0.9x |
| P/B Ratio | 3.4x |
| P/TBV Ratio | 4.3x |
| P/FCF Ratio | 65.4x |
| P/OCF Ratio | 16.6x |
| PEG Ratio | 0.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 8.7x EBITDA and 95.8x free cash flow.
| EV / Earnings | 20.3x |
|---|---|
| EV / Sales | 1.4x |
| EV / EBITDA | 8.7x |
| EV / EBIT | 11.3x |
| EV / FCF | 95.8x |
Price Statistics
The stock is down 21.88% over 52 weeks and trades 4.69% below its 50-day average.
| Beta (1Y) | 0.94 |
|---|---|
| 52-Week Change | -21.88% |
| 1-Month Change | -11.24% |
| 3-Month Change | -1.17% |
| 6-Month Change | +3.71% |
| 5-Year Change | +77.21% |
| 10-Year Change | +49.83% |
| Total Return (1Y) | -20.81% |
| Total Return (3Y CAGR) | +50.04% |
| Total Return (5Y CAGR) | +12.62% |
| Return vs SPY (1Y) | -30.35% |
| Max Drawdown (1Y) | -52.28% |
| Max Drawdown (3Y) | -52.28% |
| Sharpe Ratio (1Y) | -0.37 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $36.64 |
| 200-Day Average | $40.85 |
| 52-Week Range | $28.04 to $59.64 |
| RSI (14 Days) | 42.6 |
| Average Volume (20 Days) | 204.06K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.20x current liabilities, and total debt is 1.76x shareholder equity.
| Current Ratio | 3.20x |
|---|---|
| Quick Ratio | 1.28x |
| Debt / Equity | 1.76x |
| Debt / EBITDA | 3.09x |
| Debt / FCF | 33.91x |
Returns and Efficiency
Return on invested capital is 11.69% over the last 12 months, against a 5-year average of 7.16%.
| Return on Equity (ROE) | 24.59% |
|---|---|
| Return on Assets (ROA) | 6.78% |
| Return on Invested Capital (ROIC) | 11.69% |
| Return on Capital Employed (ROCE) | 15.06% |
| ROE (5Y Average) | 14.80% |
| ROA (5Y Average) | 3.81% |
| ROIC (5Y Average) | 7.16% |
| Asset Turnover | 1.06x |
| Inventory Turnover | 1.85x |
| Receivables Turnover | 6.69x |
| Cash Conversion Cycle | 205 days |
Taxes
Income tax took 26.56% of pretax income over the last 12 months.
| Income Tax (TTM) | $37.14M |
|---|---|
| Effective Tax Rate | 26.56% |
Scores
PAHC has an Altman Z-Score of 3.06, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.06 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $1.54B over the last 12 months is up 10.10% from the 12 months before.
| Revenue | $1.54B |
|---|---|
| Revenue Growth (YoY) | +10.10% |
| Gross Profit | $521.27M |
| Operating Income | $192.78M |
| Pretax Income | $139.86M |
| Net Income | $102.71M |
| EBITDA | $238.14M |
| EBIT | $183.52M |
| Reported EPS (TTM) | $3.27 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 27.66% of the $1.51B in total assets.
| Cash and Equivalents | $75.55M |
|---|---|
| Total Debt | $734.88M |
| Net Debt | $659.33M |
| Net Debt Per Share | $16.24 |
| Working Capital | $649.38M |
| Shareholder Equity | $417.67M |
| Book Value Per Share | $10.29 |
| Tangible Book Value | $329.33M |
| Tangible Book Per Share | $8.11 |
| Total Assets | $1.51B |
| Total Liabilities | $1.10B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $64.06M of capital spending, operating cash flow left $21.67M of free cash flow.
| Operating Cash Flow | $85.73M |
|---|---|
| Capital Expenditures | $64.06M |
| Free Cash Flow | $21.67M |
| FCF Per Share | $1.03 |
| Depreciation and Amortization | $54.62M |
| Dividends Paid | $19.47M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 12.51%, against a 5-year average of 8.46%.
| Gross Margin | 33.83% |
|---|---|
| Operating Margin | 12.51% |
| Pretax Margin | 9.08% |
| Net Margin | 6.67% |
| EBITDA Margin | 15.45% |
| EBIT Margin | 11.91% |
| FCF Margin | 1.41% |
| Gross Margin (5Y Average) | 31.23% |
| Operating Margin (5Y Average) | 8.46% |
| Net Margin (5Y Average) | 3.82% |
Growth
Revenue grew 15.79% a year over 3 years, and EPS 38.05% a year.
| Revenue Growth (3Y CAGR) | +15.79% |
|---|---|
| Revenue Growth (5Y CAGR) | +12.74% |
| EPS Growth (3Y CAGR) | +38.05% |
| EPS Growth (5Y CAGR) | +20.38% |
| FCF Growth (5Y CAGR) | -12.27% |
| Operating Income Growth (3Y CAGR) | +39.35% |
Dividends and Yields
PAHC pays out 18.97% of earnings as dividends.
| Dividend Per Share (Annual) | $0.48 |
|---|---|
| Dividend Yield | 1.37% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | 0.00% |
| Dividend Growth (5Y CAGR) | 0.00% |
| Payout Ratio | 18.97% |
| FCF Payout Ratio | 89.85% |
| Earnings Yield | 9.35% |
| FCF Yield | 1.53% |
| Shareholder Yield | 1.37% |
Peer Position
Against 11 similar companies, PAHC has the 6th highest P/E.
P/E RatioPeer median 10.3x
P/S RatioPeer median 2.0x
ROICPeer median 7.08%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.45%
Dividend YieldPeer median 0.00%
| P/E Ratio | 10.7x vs 10.3x median |
|---|---|
| P/S Ratio | 0.9x vs 2.0x median |
| ROIC | 11.69% vs 7.08% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +10.10% vs +14.45% median |
| Dividend Yield | 1.37% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 3.73% and EPS growth at 9.96% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3.73% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +9.96% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PAHC
What is PAHC's market cap?
Phibro Animal Health has a market cap of $1.42B. Its enterprise value, which adds debt and subtracts cash, is $2.08B.
What is PAHC's P/E ratio?
Phibro Animal Health has a trailing P/E ratio of 10.7x and a forward P/E of 9.8x.
How many shares of PAHC are outstanding?
Phibro Animal Health has 40.59M shares outstanding. The count is up 0.14% from a year earlier.
Does PAHC pay a dividend?
Yes. Phibro Animal Health pays $0.48 a share a year, a dividend yield of 1.37%.
How much debt does PAHC have?
Phibro Animal Health has $734.88M of total debt and $75.55M of cash and equivalents, a net debt position of $659.33M.
PAHC pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors